Amidst the resounding success of Novo’s SELECT trial, the clinical trial landscape has been inundated with a surge of innovative GLP-1 treatments. Each week witnessed the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth.  

Uniting the industry decision-makers behind the explosion of GLP-1 assets, the GLP-1-Based Therapeutics Summit served as a pivotal platform. Uniquely positioned, it was the nexus for industry decision-makers, providing invaluable insights to guide therapeutic strategies, enabling the development of the right drugs for patients at the right price. With Madrigal Pharmaceuticals attending as the first-ever company to gain approval for it's NASH therapies, this summit symbolized a landmark for the convergence of innovation and industry success. 

Built with insights from industry giants including Eli Lilly, Novo Nordisk, Amgen, Carmot Therapeutics, Altimmune, and Pfizer, this event brought together 80+ industry leaders in Product Planning, Clinical Development, Medical Research, and Commercial Strategy.